Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on February 2nd, 2022 | 11:44 CET
Gazprom, Saturn Oil + Gas, Shell - Profit from rising energy costs
Over the past year, energy costs have skyrocketed and, apart from electricity, there seems to be no end in sight. The traffic light government wants to abolish the EEG levy as early as this summer, thus ensuring that the price of electricity will fall. For oil and gas, things look less favorable. Since the EU has classified gas as climate-friendly, demand will continue to rise. 630 gas suppliers raised their prices by an average of 53% at the beginning of the year. The oil price also continues to climb, although OPEC recently said that it does not want a price of USD 100. However, it is unlikely to be resisted. We look at three oil and gas companies today.
Read
Commented by Armin Schulz on January 31st, 2022 | 13:31 CET
BioNTech, Defence Therapeutics, Mainz Biomed - After Corona, cancer is the next hype
The euphoria surrounding vaccine manufacturers has come to an end. The majority of investors believe that the end of the pandemic is near with Omicron. More and more states are abandoning restrictions and slowly returning to normalcy. If that happens, one of the biggest hypes of the last decade will come to an end. The pharmaceutical and biotech industries have earned very well from it. After the hype is before the hype. The next big story is cancer, and there are more and more cancer cases, so fighting the disease is a lucrative business. A lot is happening in this area, so we are looking at three companies today.
Read
Commented by Armin Schulz on January 28th, 2022 | 09:55 CET
Nvidia, Diamcor, BP - Buy where demand is huge
Despite a softening Bitcoin price, the situation on the graphics card market remains tense. Getting a card at the MSRP is almost impossible. Prices are falling slightly, but a rise in cryptocurrencies is enough to make prices rise again. Diamond prices have also been climbing since March 2020 and are well above pre-Corona levels. Diamonds are a girl's best friend is just as true today as it was in the 1950s. The oil price also presents itself strongly. The barrel of Brent is quoted for the first time again above USD 90. Many experts have proclaimed USD 100 as a goal. How can investors profit from this demand? We present three companies today.
Read
Commented by Armin Schulz on January 26th, 2022 | 11:17 CET
Novavax, CoinSmart, Netflix - A buy after significant setbacks?
The last few weeks have been tough for vaccine makers, cryptocurrencies and tech companies. In the case of vaccine manufacturers, concerns about a possible endemic disease caused by OmiCron was the reason for falling prices. In addition, there were the rumors about Pfizergate. Cryptocurrencies have been consolidating since early November. Allegedly, the US government is planning a crypto law, but contents are not yet known. For tech companies, the FED's expected interest rate hike, likely to be announced on January 26, brings uncertainty and makes investors rethink their investment strategy. Out of tech stocks, into value stocks. We look at one Company from each sector today.
Read
Commented by Armin Schulz on January 24th, 2022 | 12:27 CET
Deutsche Bank, CoinAnalyst, Block - Market crash, which stocks turn first?
The major indices fell sharply at the end of last week, causing significantly increased volatility. The VIX, which measures volatility, exited Friday's trading at 28.85 points. A week earlier, the value was still below 20. The DAX fell 2.9%, the S&P 2.1% and the Nasdaq 2.9%. Fears of rising interest rates and ever-higher inflation rates are causing uncertainty. In addition, there are poor figures from large companies such as Netflix. But the crypto market is also sending bearish signals. Bitcoin is on its way to test the area at USD 30,000 even though it is also considered a protection against inflation. The question becomes whether it is just the long overdue consolidation or whether the market is really crashing.
Read
Commented by Armin Schulz on January 21st, 2022 | 12:43 CET
Standard Lithium, Noram Lithium, American Lithium - Mega Demand, Mega Opportunity
The US added lithium to its list of critical minerals back in 2017. Due to the ever-increasing emergence of electric vehicles, which is tantamount to a revolution in the automotive industry, the price of lithium increased massively in 2021. Current production capacities are not sufficient to satisfy the growing lithium hunger. In addition, China dominates the global supply chain. If independence is desired, the rest of the world will have to build capacity itself. According to experts, North America could become a competitor. So today, we look at three lithium companies from the region.
Read
Commented by Armin Schulz on January 19th, 2022 | 13:14 CET
Novavax, Meta Materials, BASF - Innovations offer great return opportunities
Companies that provide innovations to solve existing problems are ideal investment targets. Filtering out suitable candidates is the most critical task for an investor. Some products require little explanation. For companies developing advanced technologies, patents can give an indication of the Company's future prospects. In any case, the market that the products can serve should be analyzed. Today, we look at three innovative companies.
Read
Commented by Armin Schulz on January 17th, 2022 | 13:22 CET
Barrick Gold, Barsele Minerals, BP - Commodities are a sleeping giant
For gold investors, 2021 was a very dull year. After breaking out to USD 2,075 in 2020, the commodity corrected and fluctuated between USD 1,600 and USD 1,900 in 2021. Medially, gold was displaced by bitcoin, and so there are many stocks in the gold sector, some of which are significantly undervalued. Oil has a similar fate. Due to climate protection, oil gets the image of a polluter, while a modern industrial society is still not possible without it. The major oil companies are no longer investing in the development of new deposits in order to improve their climate footprint. However, demand continues to rise and will remain high in the coming years. We take a look at three commodity companies from the two sectors.
Read
Commented by Armin Schulz on January 14th, 2022 | 11:06 CET
Lufthansa, wallstreet:online, Block - Shares with catch-up potential
The nervousness was palpable as the US indices fell for five days in a row. Reasons for consolidation are quickly found - the Omicron variant, inflation and the fear of rising interest rates provide uncertainty for the bulls. Especially the big tech companies would suffer from an interest rate hike, and many tech stocks were already punished and investors preferred to invest in value stocks. If the interest rate hike comes, there will likely be further markdowns in the tech sector. Today, we look at three companies that we believe could be on the verge of a turnaround.
Read
Commented by Armin Schulz on January 12th, 2022 | 13:42 CET
Bayer, XPhyto Therapeutics, MorphoSys - Which pharmaceutical companies bring returns?
Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.
Read